Kura Oncology Inc (KURA)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Kura Oncology Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 9 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 9.20 $ — 56% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
4/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% –
- Exp. sales growth 3Y > 5% 78.3%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 78.3%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% -160.0%
- ROCE > 15% -48.9%
- Expected return > 10% 63.0%
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
3 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years no data
- More than 10% revenue growth is expected for the coming year 125.8% passed
- Share count grows by less than 3% a year 9.4% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -79.5% failed
- Gross margin at 40% or higher and without meaningful erosion no data
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 647 m net cash passed
- Operating cash flow covers the profits of the last three years 551 m failed
- Return on capital at 15% or higher, or up versus two years ago -48.9% failed
- Insiders hold at least 10% or are net buyers 1.4% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 238.8% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 15
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -3.44 | -3.72 – -2.78 | 95 | -8.3% | 9 |
| 12/31/2027 | -2.58 | -3.48 – -2.08 | 215 | 25.1% | 9 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.89 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.22 | – | 54 | 4,142.80 | -35.70 | 269 | 269 |
| 2025: Q1 | -0.66 | – | 14 | – | -407.10 | -72 | -72 |
| 2025: Q2 | -0.75 | – | 15 | – | -432.50 | -29 | -30 |
| 2025: Q3 | -0.85 | – | 21 | – | -357.20 | -81 | -83 |
| 2025: Q4 | -0.92 | – | 17 | -67.80 | -467.20 | 117 | 115 |
| 2026: Q1 | -0.83 | – | 18 | 29.50 | -401.50 | -86 | -86 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 0 | -28 | -28 | -1.47 | -25 | 57 | 70 |
| 2017 | 0 | -36 | -35 | -1.52 | -28 | 80 | 96 |
| 2018 | 0 | -63 | -60 | -1.72 | -49 | 161 | 182 |
| 2019 | 0 | -67 | -63 | -1.51 | -55 | 219 | 242 |
| 2020 | 0 | -92 | -90 | -1.69 | -70 | 611 | 647 |
| 2021 | 0 | -131 | -130 | -1.97 | -105 | 507 | 534 |
| 2022 | 0 | -140 | -136 | -2.03 | -110 | 420 | 456 |
| 2023 | 0 | -166 | -153 | -2.08 | -125 | 397 | 449 |
| 2024 | 54 | -193 | -174 | -2.02 | 134 | 414 | 760 |
| 2025 | 67 | -304 | -279 | -3.18 | -64 | 174 | 738 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Kura Oncology, Inc., ein biopharmazeutisches Unternehmen in der klinischen Phase, entwickelt Medikamente zur Krebsbehandlung.
| CEO Insider Trades (12 Mo.) | buying own stock |
|---|---|
| Employees | 260 |
| Headquarters | San Diego, CA |
| Address | 4930 Directors Place, 92121 San Diego, United States |
| Phone | 858 500 8800 |
| Website | kuraoncology.com |
| IPO Date | 22. Sep 2015 |
| ISIN | US50127T1097 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Troy Edward Wilson J.D., Ph.D. | Chairman, CEO & President | 1969 |
| Kathleen Ford | Chief Operating Officer | 1947 |
| Brian T. Powl M.B.A., M.S. | Chief Commercial Officer | 1974 |
| Thomas Doyle | Senior Vice President of Finance & Accounting | 1971 |
| Francis J. Burrows Ph.D. | Chief Scientific Officer | 1962 |
| Greg Mann | Senior Vice President of Investor Relations & Corporate Affairs | – |
| Teresa Brophy Bair Esq., J.D. | Chief Legal Officer & Corporate Secretary | 1971 |
| Roger Bakale Ph.D. | Senior Vice President of Manufacturing & Supply Chain | – |
| Mollie Leoni M.D. | Chief Medical Officer | 1978 |
| Samir Vattompadam M.S. | Senior Vice President of Global Program Leadership | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.